apalutamide: Clinical Trials

61 trials of apalutamide, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

18 completed, 14 active not recruiting, 13 recruiting, 5 terminated. 61 Phase 2, 3 Phase 1, 1 Phase 3.

By phase and status

PhaseTrialsStatus
Phase 261Completed 18, Active not recruiting 14, Recruiting 13, Terminated 5, Unknown 4, Withdrawn 4, Not yet recruiting 3
Phase 13Active not recruiting 1, Completed 1, Recruiting 1
Phase 31Active not recruiting 1

Follow apalutamide: new trials by email Literature Review of apalutamide trials Research Report on apalutamide

Trials (filtered) newest first · largest first

All 61 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
A Prospective Study Based on Spatial Multi-omics to Predict the Efficacy of ADT Combined With Second-generation Novel Hormonal Agents in Metastatic Hormone-sensitive Prostate Cancer.
ADT plus abiraterone or other ARPIs(apalutamide, enzalutamide, rezvilutamide, darolutamide) - Metastatic Hormone-Sensitive Prostate Cancer
Phase 2Not yet recruitingAnhui Medical University402026-10-012026-08-31
Study of Oral MRT-2359 With Apalutamide in Prostate Cancer
Oral MRT-2359, Apalutamide - Castration-Resistant Prostate Cancer (CRPC), Castration-Resistant Prostate Cancer
Phase 2RecruitingMonte Rosa Therapeutics, Inc252026-08-182026-11-05
Exploration of Treatment Effect of Novel Hormone Therapy Combined With Local Treatment Based on PSMA PET/CT Evaluation in mHSCP Patients
Local treatment, Gonadotropin releasing hormone analog (GnRHa) + Novel hormone therapy (abiraterone, apalutamide or rezvilutamide). - Prostate Cancer Metastatic Disease
Phase 2RecruitingShanghai General Hospital, Shanghai Jiao Tong University School of Medicine1922025-08-012026-03-25
Investigating SX-682 in Combination With Apalutamide in Metastatic Castration-resistant Prostate Cancer
SX-682, Apalutamide - Metastatic Castrate-Resistant Prostate Cancer (mCRPC)
Phase 1 / Phase 2RecruitingInstitute of Cancer Research, United Kingdom782025-04-282026-09-08
Adaptive Androgen Deprivation and Docetaxel in Metastatic Castration Sensitive Prostate Cancer
Luteinizing Hormone-Releasing Hormone (LHRH) analog, Androgen Receptor Signal Inhibitor (ARSI), Docetaxel - Metastatic Castration Sensitive Prostate Cancer
Phase 2Active not recruitingH. Lee Moffitt Cancer Center and Research Institute252025-01-102026-04-01
Surgical Treatment With or Without Apalutamide in Subjects With High Risk Prostate Cancer Who Are Candidates for Radical Prostatectomy and Staged as Oligometastatic With PSMA-PET
Apalutamide, Androgen receptor (AR) inhibitor - High Risk Prostate Cancer
Phase 2RecruitingMarco Oderda942024-11-252025-01-06
Stereotactic Body Radiation Therapy Plus Immediate or Delayed Androgen Receptor Pathway Inhibitor and Androgen Deprivation Therapy or Salvage Radiation Therapy for the Treatment of Prostate Cancer, DIVINE Trial
Abiraterone, Apalutamide, Biospecimen Collection - Recurrent Castration-Sensitive Prostate Carcinoma, Recurrent Prostate Cancer
Phase 2RecruitingMayo Clinic5322024-06-032026-07-20
Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study
Apalutamide, Biopsy, Biospecimen Collection - Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma
Phase 2TerminatedUniversity of Washington82024-05-232026-10-19
Hormone Therapy (Apalutamide) and Image-guided Stereotactic Body Radiation Therapy for the Treatment of Patients With Prostate Cancer, HEATWAVE Trial
Apalutamide, Biospecimen Collection, Computed Tomography - Prostate Adenocarcinoma, Stage II Prostate Cancer AJCC v8
Phase 2RecruitingJonsson Comprehensive Cancer Center952024-03-282026-07-17
Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc
AR Blockade, Carotuximab - Castration-resistant Prostate Cancer
Phase 2RecruitingEdwin Posadas, MD1162023-12-272026-10-05
Maximal Cytoreductive Therapies on Post-treatment Metastases in Pts With mHSPC During Apalutamide Plus ADT Treatment
apalutamide, androgen deprivation therapy, cytoreductive radical prostatectomy with/without pelvic lymph node dissection - Metastatic Prostate Cancer, Castration-Sensitive Prostate Cancer
Phase 2Not yet recruitingFudan University472023-05-012023-02-08
TherApeutics in Early ProState Cancer (TAPS02)
Apalutamide Oral Tablet [Erleada], Placebo - Prostate Cancer
Phase 2RecruitingCambridge University Hospitals NHS Foundation Trust902023-04-242025-06-20
Adjutant Apalutamide Plus ADT in Post-RP Patients With High Risk of Recurrence (ARES Study)
Apalutamide 60mg Tab, Androgen deprivation therapy(ADT) - Prostate Cancer, Biochemical Recurrence
Phase 2Not yet recruitingThe Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School1032023-04-012023-03-21
Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer
Abiraterone, Enzalutamide, Apalutamide - Prostate Cancer, Metastatic Prostate Cancer
Phase 2Active not recruitingH. Lee Moffitt Cancer Center and Research Institute262023-02-142026-09-15
Abiraterone, Enzalutamide, or Apalutamide in Castrate-sensitive Prostate Cancer.
Abiraterone acetate, Apalutamide, Enzalutamide - Metastatic Cancer, Neoplasm, Prostate
Phase 2RecruitingSun Pharmaceutical Industries Limited1922022-08-312026-06-15
Study of AZD5305 When Given in Combination With New Hormonal Agents in Patients With Metastatic Prostate Cancer
AZD5305, Enzalutamide, Abiraterone Acetate - Metastatic Prostate Cancer
Phase 1 / Phase 2Active not recruitingAstraZeneca1742022-06-022026-08-26
Enhanced Systemic Combined With Local Treatment for Primary and Metastatic Lesions in Oligo-metastatic Prostate Cancer
Leuprolide acetate, Goserelin acetate, Triptorelin acetate - Prostate Cancer
Phase 2UnknownFudan University1602022-04-012022-03-16
Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
Apalutamide, Cetrelimab - Small Cell Neuroendocrine Carcinoma, Prostate Cancer
Phase 2TerminatedRahul Aggarwal22022-03-162025-05-15
The Finnish National Study to Facilitate Patient Access to Targeted Anti-cancer Drugs
Alectinib, Cobimetinib, Vismodegib - Advanced Cancer, Solid Tumor
Phase 2RecruitingHelsinki University Central Hospital2502021-12-102026-11-10
Genomic Biomarker-Selected Umbrella Neoadjuvant Study for High Risk Localized Prostate Cancer
Apalutamide 60mg Tab, Abiraterone Acetate 250mg, Prednisone 5mg Tab - Prostate Cancer
Phase 2RecruitingUniversity of British Columbia3152021-09-212026-08-14

Showing 20 of 61. Sign in to see all of them.

Conditions studied

Prostatic Neoplasms (49)  ·  Neoplasm Metastasis (3)  ·  Prostatic Neoplasms, Castration-Resistant (2)  ·  Adenocarcinoma (1)  ·  Bulbo-Spinal Atrophy, X-Linked (1)  ·  Carcinoma, Small Cell (1)  ·  Hematologic Neoplasms (1)  ·  Neoplasms (1)  ·  Salivary Gland Neoplasms (1)  ·  Small Cell Lung Carcinoma (1)

Sponsors

M.D. Anderson Cancer Center (7)  ·  Dana-Farber Cancer Institute (3)  ·  University of Washington (3)  ·  Aragon Pharmaceuticals, Inc. (2)  ·  Fudan University (2)  ·  H. Lee Moffitt Cancer Center and Research Institute (2)  ·  Janssen Research & Development, LLC (2)  ·  Jonsson Comprehensive Cancer Center (2)  ·  Memorial Sloan Kettering Cancer Center (2)  ·  The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School (2)  ·  VA Office of Research and Development (2)  ·  Andrew J. Armstrong, MD (1)  ·  Anhui Medical University (1)  ·  AstraZeneca (1)  ·  CCTU- Cancer Theme (1)

Countries

United States (41)  ·  China (6)  ·  United Kingdom (4)  ·  Belgium (2)  ·  Brazil (2)  ·  Canada (2)  ·  Italy (2)  ·  Australia (1)  ·  Austria (1)  ·  Finland (1)  ·  France (1)  ·  Germany (1)  ·  Japan (1)  ·  Singapore (1)  ·  Switzerland (1)

Top investigators

Amar Kishan (2)  ·  Jingsong Zhang, MD, PhD (2)  ·  Michael Schweizer (2)  ·  Rahul Aggarwal, MD (2)  ·  Abhishek Solanki, MD MS (1)  ·  Ana Aparicio (1)  ·  Bagi Jana, MD (1)  ·  Christopher Logothetis (1)  ·  Daniel J. George, MD (1)  ·  Dingwei Ye, Doctoral (1)  ·  Diogo A Bastos, MD (1)  ·  Edwin Posadas, MD FACP (1)  ·  Eleni Efstathiou (1)

Results publications

PMID 27068431, PMID 27160947, PMID 28633425, PMID 29384722, PMID 29606109, PMID 29723398, PMID 29740894, PMID 30935383, PMID 31122212, PMID 32356465, PMID 33683939, PMID 34655838, PMID 35091711, PMID 36000794, PMID 36055231, PMID 36472728, PMID 38161319, PMID 38421243, PMID 38421252, PMID 38494380, PMID 38796422, PMID 38824003, PMID 39036382, PMID 39074346, PMID 39088398, PMID 39293393, PMID 39643549, PMID 39804646, PMID 39857987, PMID 40177596, PMID 40387589, PMID 40677104, PMID 40693904, PMID 41062343, PMID 41202201, PMID 41228234, PMID 41296089, PMID 41529384, PMID 41623173, PMID 41625480, PMID 41651176, PMID 41779146, PMID 42117295, PMID 42186347, PMID 42252348

NIH funding

2016 (2), 2017 (2), P30CA015704 (2), 2023 (1), I01CX002277 (1), P30CA023074 (1), P30CA072720 (1), R01CA286127 (1), R01CA300454 (1), U10CA180868 (1), UG1CA242596 (1)